Last updated 2 days ago

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

390 patients around the world
Available in Brazil, United States
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer. Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
Astellas Pharma Global Development, Inc.
390Patients around the world

This study is for people with

Urologic cancer
Urothelial cancer
Bladder Cancer
Muscle-Invasive Bladder Cancer

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0.
Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline.
Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens.
Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy.
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy.
Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC.
Prior pelvic radiation for any reason.
Inadequate bladder function.
Other active malignancies within 3 years prior to randomization.
Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs).
Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor.
Uncontrolled diabetes.
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted.
Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization.
Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin.
Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome).
Active keratitis or corneal ulcerations.
History of autoimmune disease that has required systemic treatment in the past 2 years.
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
Prior allogeneic stem cell or solid organ transplant.
Received a live attenuated vaccine within 30 days prior to randomization.
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy